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ABSTRACT
CD95, a member of the death receptor family initiates a caspase-dependent 
apoptosis, when activated by its ligand CD95L, thought to negatively regulate 
erythrocyte production in the bone marrow. We have previously shown that CD95 is 
overexpressed in two thirds of patients with a lower risk myelodysplastic syndrome 
(MDS) and that resistance to erythropoiesis-stimulating agents (ESA) is linked to 
poor residual erythropoiesis. In the present study, we show that CD95 overexpression 
and previous transfusion are independent predictive factors of ESA resistance. To 
investigate an alternative therapeutic strategy of anemia in ESA-resistant patients, 
we have conducted a preclinical study of the effects of APG101, a fusion protein 
consisting of the extracellular domain of human CD95 and the Fc region of human 
IgG1 on MDS erythropoiesis in vitro. APG101 increases the number of burst-forming 
unit-erythroid (BFU-E) progenitors derived from CD34+ progenitors in liquid culture 
and improves overall proliferation rate of erythroid precursors by inhibiting apoptosis. 
APG101 rescues BFU-E growth in MDS patients presenting with attrition of erythroid 
progenitors at baseline, independently of CD95 or CD95L expression level. Our data 
show that overexpression of CD95 at diagnosis is a hallmark of ESA resistance and 
that severe impairment of erythropoiesis is predictive of erythroid response to APG101 
in vitro. These data provide a rationale for further clinical investigation of APG101 in 
an attempt to treat anemia in lower risk MDS patients.
INTRODUCTION
CD95 (Fas, APO-1, TNFRSF6, APT1) belongs 
to the death receptor family. When bound to its ligand 
CD95L (FasL), it initiates the assembly of a signaling 
complex that activates initiating caspase 8 or 10 and 
leads to apoptosis. The CD95 pathway is essential to 
eliminate auto-reactive B lymphocytes, controlling T 
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cell homeostasis and negatively regulating erythrocyte, 
neutrophil and megakaryocyte production by inducing 
cell death in the bone marrow. [1] CD95-dependent 
apoptosis is thought to occur in the erythroblastic 
island when the erythropoietin concentration decreases 
locally due to the expansion of mature erythroblasts 
which trap the hormone. CD95L expressed on the more 
mature erythroblasts induces apoptosis of the immature 
erythroblasts expressing CD95. [2, 3] We have previously 
reported that CD95 is overexpressed on CD34+ progenitors 
and erythroblasts in two thirds of patients with lower risk 
myelodysplastic syndromes (MDS), a clonal disorder of 
the hematopoietic stem cell (HSC) that evolves to acute 
myeloid leukemia (AML) in 30% of cases. Furthermore, 
the expression of CD95L becomes upregulated in mature 
erythroblastic precursors during in vitro differentiation of 
CD34+ progenitors. Inhibition of CD95 activation prevents 
massive apoptosis of immature erythroblastic precursors 
that is at least partly responsible for peripheral blood 
anemia. [4, 5]
In early MDS, the aim of treatments is to correct 
cytopenias. Therefore, erythropoiesis-stimulating agents 
(ESA) are largely used despite these treatments are not yet 
approved by the FDA/EMEA in this indication. Less than 
500 UI/L serum erythropoietin (EPO) level and less than 
2 red blood cell (RBC) units per month were associated 
with the best response rates that hardly reached 39 to 62% 
in terms of transfusion independency or hematological 
improvement of the erythroid lineage (HI-E) according 
to IWG criteria. [6, 7, 8, 9] A decision model based on 
these two parameters has been proposed and validated by 
the Nordic group, [8] and has recently been improved by 
the addition of flow cytometry score. [10] Significantly 
higher response rate was observed in MDS with less than 
10% blasts, low and int-1 International Prognostic Scoring 
System (IPSS), and red blood cell (RBC) transfusion 
independence in studies from the Groupe Francophone 
des Myélodysplasies. [9] In this cohort, a shorter interval 
between diagnosis and treatment could support a positive 
impact of ESA on overall survival. [9, 11, 12] However, 
limited response rate suggests that other factors may 
influence the response. We have previously identified 
severe impairment of erythropoiesis as a hallmark of 
patients who will fail to response to ESA. [13] Thus, to 
cure anemia in these patients, alternative therapeutic 
strategies are necessary.
In the present observational study, a preclinical 
research was performed to investigate the impact of 
the recombinant glycosylated fusion protein, APG101, 
consisting of the extracellular domain of human CD95 
linked to the Fc domain of human IgG1 (CD95-Fc) on 
erythropoiesis in patients with lower risk MDS in vitro. 
APG101 effectively binds to CD95L expressed on target 
cells as well as to functionally active ligand in solution, 
and thus inhibiting CD95 activation. We show here that 
APG101 rescued erythropoiesis in MDS patients with 
impaired erythropoiesis independently of the expression 
level of CD95 or CD95L.
RESULTS
CD95, but not CD95L is overexpressed in lower 
risk MDS
We compared the expression level of CD95 on 
CD45low bone marrow cells in a large cohort of 250 MDS 
including 162 low/int-1 IPSS and 30 int-2/high IPSS 
MDS before treatment (Supplementary Table S1) and 
30 controls. Median CD95 RFI level was significantly 
higher in IPSS low/int-1 MDS compared to controls 
(P = 0.043) (Figure 1A). Accordingly, the median 
value of CD95 was also significantly more elevated in 
very high/high IPSS-R subgroup compared to controls 
(P = 0.023) and had a trend to be also higher in very 
low/low/intermediate IPSS-R subgroups (P = 0.054) 
(Supplementary Figure S1A).
We also quantified the expression of membrane-
bound CD95L on CD45low bone marrow cells in 82 MDS 
before treatment and 18 controls (Supplementary Table 
S1). We found that the median RFI of CD95L was similar 
between IPSS low/int-1 MDS, int-2/high MDS and controls 
groups (Figure 1B) and similar between the IPSS-R very 
low/low/intermediate, very high/high and controls groups 
(Supplementary Figure S1B).
Genetic control of CD95 expression
Two single nucleotide polymorphisms -1377 
(rs2234767) G>A and -670 (rs1800682) A>G located 
in the promoter core of the gene have been reported 
to control CD95 expression level. [15, 16, 17, 18] 
To investigate this point in MDS, we screened 129 
samples from this cohort for their polymorphism at 
-1377 and -670 loci. The frequency of -1377A allele 
appeared to be less represented in MDS (10.8%) 
compared to the current frequency in Caucasians 
(15%) while the -670G allele was equally represented 
in MDS (49.2%) compared to controls (49.0%). [15, 
17, 18] We then compared CD95 expression level in 
each genotype. We found that the median RFI value 
was not significantly different between the -1377 
GG vs-1377 GA/AA genotypes (Mann-Whitney 
test, P=0.118). By contrast, the median CD95 RFI 
was significantly higher in the group with -670 AA 
genotype compared to the group with -670 AG/GG 
genotypes (Mann-Whitney test, P=0.021; Table 2). 
As all subjects with a -670 AA genotype had a -1377 
GG genotype, the -1377G/-670A ancestral haplotype 
was associated with a higher CD95 expression level 
than the -1377A/-670G haplotype. These data suggest 
that a genetic predisposition could contribute to CD95 
overexpression in MDS patients.
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CD95 expression level at diagnosis is predictive 
of response to ESA, but not predictive of overall 
or event-free survival
We then investigated the impact of CD95 expression 
on clinical presentation at diagnosis, response to ESA 
treatment and survival in 162 lower risk MDS patients 
(Table 1). We have previously established that the 
threshold of CD95 expression predictive of MDS was a 
RFI of 1.7 in comparison with a large series of controls. 
[19] Here we found that 100/162 patients (61.7%) had a 
CD95 RFI ≥ 1.7, further denominated as CD95high patients. 
There was no significant difference of age, sex ratio, past 
history of chemo or radiotherapy, blood parameters, 
bone marrow parameters, dysplasia, karyotype, IPSS 
and IPSS-R between CD95high and CD95low patients 
(Table 1). However, the representation of WHO subtypes 
was unbalanced (Fisher’s exact test; P = 0.011), with 
a more frequent representation of RCMD in CD95high 
patients than in CD95low patients.
In the whole cohort, follow-up information was 
available for 204/250 (81.6%) and the median follow-up 
was 57.2 (IQR: 25.6 – 87.3) months. Clinical follow-up 
data were available for 156/162 (96.3%) low/int-1 MDS 
patients including 97 (62.2%) with high CD95 expression 
and 59 (37.8%) with low CD95 expression. The median 
follow-up in the low/int-1 cohort was 60.0 (IQR: 32.5 – 
90.7) months. As shown in Table 1, treatments including 
RBC transfusions, ESA, lenalidomide, azacitidine, low 
dose aracytine, intensive chemotherapy and allo-HSCT 
were equivalent in CD95low and CD95high patients. No 
difference of overall survival (P = 0.224) or event-free 
survival (P = 0.195) was found between the two groups 
(Figure 2A & 2B). Finally, none of the studied genotypes 
at -1377 or -670 loci had any impact on overall survival or 
event-free survival (Supplementary Figure S2).
One hundred and eighteen patients were treated 
with ESA and 75/118 (63.6%) were responders after 
3 months of treatment according to IWG2006 criteria. 
CD95low patients (33/43; 76.7%) were more frequently 
responders to treatment than CD95high patients (41/75; 
54.7%; P = 0.017; Table 1). In univariate analysis, the 
predictors of ESA resistance were serum EPO level over 
100 IU/mL (available for only 80 patients; P = 0.008) and 
previous transfusion (P = 0.001). To further explore the 
link between ESA response and C95 expression, we used 
a logistic regression to adjust on the presence or absence 
of previous transfusion. High CD95 expression level 
(OR: 2.5 [95%CI: 1.1 – 6.0], P = 0.036) and previous 
transfusion (OR: 2.7 [95%CI: 1.1 – 6.3], P = 0.025) 
remained independent predictors of ESA resistance.
Effects of APG101 on erythroblast proliferation, 
differentiation and apoptosis
We have shown here that CD95 overexpression was 
predictive of lower response rate to ESA in the present 
cohort of 118 low/int-1 MDS patients treated by ESA. 
Thus, an alternative therapeutic strategy must be used to 
cure anemia in these patients. In this aim, we investigated 
the effect of APG101, a soluble dimer of the extracellular 
domain of human CD95 in fusion with the Fc domain of 
human IgG1. Bone marrow erythroid progenitors from 
5 patients with MDS (2 RA, 2 RCMD, 1 RARS) and 3 
Figure 1: A. Membrane CD95 expression in MDS bone marrow. CD95 expression was quantified in the CD45low cell population by 
flow cytometry. Results as ratios of fluorescence intensity (RFI) in 30 controls and 192 patients including 162 low/int-1 and 30 int-2/high 
MDS. B. Membrane expression of CD95 ligand (CD95L) in MDS bone marrows. CD95L expression was quantified in the CD45low cell 
population. Results as RFI in 41 low/in-1 and 9 int-2/high MDS patients and 18 controls. Box plots with horizontal bars indicating the 
median and 1st and 99th centiles. Unpaired Student t-test or Mann-Whitney-test for P values.
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Table 1: Clinical and biological parameters of 162 low/int-1 MDS patients according to CD95 expression level 
Parameters CD95 cohort (n=162) CD95low cohort 
(n=62)
CD95high cohort 
(n=100)
P
Demography
Age (median [IQR25-
75%]) 73 [67-80] 74 [69 - 78] 72 [66 - 80] 0.854
Sex ratio M/F 1.6 (100/62) 1.5 (37/25) 1.7 (63/37) 0.672
Past history of chemo or 
radiotherapy yes/no (%) 16/123 (11.5) 9/42 (17.7) 7/81 (8.0) 0.084
WHO 2008 % n (%)
5q- syndrome/RA 39 (24.1) 19 (30.7) 20 (20.0) 0.011*
RARS/RCMD-RS 44 (27.1) 21 (33.9) 23 (23.0)
RCMD 33 (20.4) 5 (8.1) 26 (26.0)
RAEB1 45 (27.9) 17 (27.3) 28 (28.0)
MDS-U 1 (0.6) 0 (0) 1 (1)
Blood parameters 
(median [IQR])
Hemoglobin g/dL 9.9 [9.0 - 10.7] 9.9 [9.2 - 10.7] 10.0 [8.9 - 10.9] 0.985
Mean corpuscular 
volume fL 101 [93 - 107] 100 [90 - 108] 102 [94 - 107] 0.153
Neutrophils G/L 2.1 [1.2 - 3.6] 2.4 [1.4 - 3.7] 2.0 [1.2 - 3.1] 0.393
Platelets G/L 212 [126 - 296] 225 [108 - 323] 199 [133 - 274] 0.627
Reticulocytes G/L 47.3 [29 - 59.6] 47 [24 - 63] 49 [29 - 58] 0.921
Bone marrow 
parameters
Richness n (%) poor/
medium/high
11 (7.7) / 76 (53.2) / 
56 (39.2) 
5 (9.8) / 28 (54.9) / 18 
(35.3)
6 (6.5) / 48 (52.2) / 38 
(41.3)
0.661*
Blasts median (% 
[IQR]) 3 [2 - 5] 3 [2 - 5] 3 [2 - 5] 0.736
Erythroblasts median  
(% [IQR]) 29 [20 - 41] 28 [22 - 39] 31 [20 - 42] 0.783
Bone marrow 
dysplasia yes/no (%)
Dyserythropoiesis 105/32 (76.6) 37/12 (75.5) 68/20 (77.3) 0.815
Dysgranulopoiesis 88/37 (70.4) 29/15 (65.9) 59/22 (72.8) 0.418
Dysmegakaryopoiesis 76/49 (60.8) 24/20 (54.6) 52/29 (64.2) 0.291
Karyotype normal 
(yes/no) 104/58 (64.2) 41/21 (66.1) 63/37 (63.0) 0.686
Karyotype IPSS n (%)
Good 129 (83.8) 52 (86.7) 77 (81.9) 0.787*
Intermediate 24 (15.6) 8 (13.3) 16 (17.0)
Poor 1 (0.6) 0 (0) 1 (1.1)
(Continued )
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Parameters CD95 cohort (n=162) CD95low cohort 
(n=62)
CD95high cohort 
(n=100)
P
Karyotype IPSS-R 
n (%)
Very good 11 (6.9) 4 (6.5) 7 (7.2) 0.787*
Good 128 (80.5) 52 (83.9) 76 (78.4)
Intermediate 18 (11.3) 6 (9.7) 12 (12.4)
Poor 0 (0) 0 (0) 0 (0)
Very poor 2 (1.3) 0 (0) 0 (2.1)
IPSS n (%)
low 93 (57.4) 40 (64.5) 53 (53.0) 0.151
int-1 69 (42.6) 22 (35.5) 47 (47.0)
IPSS-R n (%)
Very good (0-2) 45 (28.3) 21 (33.9) 24 (24.7) 0.396*
Good (>2-5) 87 (54.7) 33 (53.2) 54 (55.7)
Intermediate (>5-7) 22 (13.8) 8 (12.9) 14 (14.4)
Poor (>7-9) 4 (2.5) 0 (0) 4 (4.1)
Very poor (>9-18) 1 (0.6) 0 (0) 1 (1.0)
Treatments yes/no (%)
RBC transfusions 74/63 (54.0) 25/27 (48.1) 49/36 (57.7) 0.275
Erythropoiesis-
stimulating agents 118/23 (83.7) 43/9 (82.7) 75/14 (84.4) 0.807
Lenalidomide 35/92 (27.6) 13/36 (26.5) 22/56 (28.2) 0.837
Demethylating agents 25/108 (18.8) 7/44 (13.7) 18/64 (22.0) 0.238
Low dose aracytine 4/129 (3.0) 1/50 (2.0) 3/79 (3.7) 1.000
Intensive chemotherapy 3/126 (2.3) 0/49 (0) 3/77 (3.8) 0.288
Allo HSC 
transplantation 3/126 (2.3) 1/48 (2.0) 2/78 (2.5) 1.000
Response to ESA (yes/
no) 75/43 (63.6) 33/10 (76.7) 41/34 (54.7) 0.017
Overall survival 
in months(median 
[95%CI]) (n=156)
108.1 [75.5 - 128.4] 111.1 [75.5 - ***] 90.2 [64.1 - 128.4]
The threshold for CD95 RFI was 1.7. Continuous variables are expressed as median [interquartile range 25-75% or 95% 
confidence interval] and analyzed by using Student t-test or ANOVA test. Non parametric variables are expressed as 
percentages and analyzed by using Chi-square or Fisher’s exact tests. P values <0.05 were considered as significant. * for 
Fisher’s exact test. IQR: interquartile range; CI: confidence interval; WHO: World Health Organization; RA: refractory 
anemia; MDS-U: undefined MDS; RARS: refractory anemia with ring sideroblasts; RCMD: refractory cytopenia with 
multilineage dysplasia; RCMD-RS: RCMD with ring sideroblasts; RAEB1: RA with excess of blast lower than 10%; RBC: 
red blood cells; HSC: hematopoietic stem cell; IPSS: International Prognosis Scoring System; IPSS-R: IPSS-revised.
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controls were expanded until day 9. [4] In all MDS cases, 
the expression of CD95 (RFI) was a range between 1.8 and 
2.7. CD95 expression was higher in MDS [range: 1.7 – 
2.8] compared to controls [range: 0.8 – 1.0] and increased 
during MDS erythroid progenitor amplification while it 
remained lower in control cultures (not shown). At day 5 
of the liquid culture, erythroid progenitors of BFU-E-type 
were quantified in clonogenic assays in the presence of 
increasing concentrations of APG101. As shown in Figure 
3A, mean BFU-E number was significantly lower in MDS 
compared to controls. APG101 induced a dose-dependent 
increase of BFU-E growth in MDS samples but not in the 
controls. BFU-E number reached the number of BFU-E in 
normal controls at a APG101 concentration of 10 μg/mL. 
From day 10 until day 17, we added APG101 (10 μg/mL) 
to the liquid culture to investigate the impact of the drug 
on erythroblast differentiation driven by erythropoietin 
and insulin. We observed that APG101 improved the 
proliferation rate without a significant effect on the kinetic 
of differentiation (Figures 3B & 3C). The repartition of the 
different erythroid precursor categories identified either 
by cytological examination of MGG-stained cytospins or 
flow cytometry was similar in the presence of APG101 
or the control vehicle (Figure 3C). By contrast, APG101 
reduced by 30% the level of apoptosis of immature 
precursors while it did not demonstrate any effect on the 
apoptotic level of mature precursors (Figure 3D). These 
results show that APG101 inhibited erythroblast apoptosis 
thus rescuing erythroid cell growth.
APG101 effects on hematopoietic progenitor 
growth in vitro
Considering the rescue of BFU-E harvested from 
liquid culture by APG101, we further evaluated the effects 
of increasing concentrations of APG101 on BMMNC-
derived clonogenic progenitors in 20 MDS patients (3 
5q- syndrome, 3 RA, 1 RARS, 2 RCMD-RS, 5 RCMD, 
6 RAEB1) and 5 controls. Among these patients, 15 
received ESA and 14 were primary (n=6) or secondary 
(n=8) resistant to this treatment. The mean baseline 
number of BFU-E was significantly different (5.4 ± 1.3 
colonies per 105 BMMNC) in 15 MDS further referred 
as “low” compared to controls (33.5 ± 12.9 colonies per 
105 BMMNC; Mann-Whitney, P = 0.005) while in 5 cases 
(3 RCMD/RCMD-RS, 2 RAEB1) further referred as 
“normal”, the mean number of BFU-E (38.2 ± 5.5 colonies 
per 105 BMMNC) was similar to that of controls (Mann-
Whitney, P = 0.429). In these 15 cases (11 5q- syndrome/
RA/RCMD, 4 RAEB1), CFU-E and CFU-GM numbers 
at baseline were also significantly lower than that of 
controls and “normal” MDS (Supplementary Figure S3) 
while CFU-L number was as low as in the controls group 
and lower than in the “normal” MDS group. There was 
no significant difference of WHO classification or CD95 
expression between the 15 patients with low erythropoiesis 
at baseline versus the 5 patients with normal initial 
erythropoiesis (Fisher’s exact test; P=0.612). Eleven 
among 15 patients with low erythropoiesis (73.3%) 
received ESA and all of them were resistant to this 
treatment.
APG101 induced a dose-dependent increase of 
BFU-E in these “low” MDS, but neither in the “normal” 
MDS nor in the controls group (Kruskal-Wallis test; 
P<0.001; Figure 4A). The number of CFU-E, CFU-
GM, and more interestingly the number of CFU-L 
corresponding to leukemic cell clusters remained 
unchanged in every subgroup. (Figure 4B – 4D). 
The presence of a low number of BFU-E at baseline 
was significantly associated with in vitro response to 
APG101 among the 20 MDS patients (Fisher’s exact 
test, P = 0.031) and also among the 14 ESA-resistant 
patients (P = 0.027).
Low clonogenic progenitor number at baseline, 
but not CD95 or CD95L expression level is 
predictive of the response to APG101
Then, we compared CD95 and CD95L expression 
in the two groups of responder and non-responder patients 
to in vitro treatment with APG101. As shown in Figure 
5A, the median CD95 RFI and the median CD95L RFI 
were not significantly different between MDS samples 
in which APG101 improved BFU-E growth compared to 
Table 2: CD95 expression levels according to CD95 gene polymorphisms of the core promoter -1377 G>A and -670 
A>G
CD95 gene SNP n (%) CD95 RFI median 
[IQR 25-75]
P
-1377 GG 102 (79.1) 2.1 [1.6 - 2.7] 0.118
-1377 GA/AA 27 (20.9) 1.6 [1.6 - 2.5]
-670 AA 32 (24.8) 2.5 [1.7 - 2.9] 0.021
-670 AG/GG 97 (75.2) 2.0 [1.4 - 2.6]
Genotypes were determined for 129 MDS patients. Median CD95 RFI were compared using Mann-Whitney test. P values < 
0.05 were considered as significant. IQR: Inter-Quartile Range.
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those in which it did not. By contrast, baseline number of 
BFU-E, CFU-E, CFU-GM and CFU-L was significantly 
lower in responders, suggesting that APG101 could rescue 
erythropoiesis in patients which hematopoiesis is severely 
impaired. Thus, we identified low clonogenic progenitor 
number at baseline as a good predictor of the response to 
APG101 (Figure 5B).
DISCUSSION
In the present work, we show that CD95 
overexpression is a biomarker of ESA resistance. 
Furthermore, patients with ESA resistance exhibit a severe 
impairment of their hematopoiesis. [13] APG101, a CD95 
fusion protein, efficiently rescues the growth of MDS 
immature erythroid progenitors of BFU-E type when their 
baseline number is low, independently of the expression 
level of CD95 or CD95L.
Transcription of CD95 expression is genetically 
determined. The presence of an A nucleotide at -1377 or a 
G nucleotide at -670 disrupts the docking of transcription 
factors SP1 or STAT1 to CD95 promoter, respectively. [16] 
Therefore, a lower transcription efficacy is observed when 
-1377A and -670G alleles are expressed. Here, we showed 
the genetic predisposition of patients with -1377G/-670A 
haplotype to a higher CD95 expression level than patients 
with -1377A/-670G haplotype. The genetic polymorphism 
-1377G>A in the core promoter of CD95 gene that reduces 
the expression level of CD95 has been associated with the 
risk of developing AML. [16] This polymorphism also 
predicts a worse prognosis in acute promyelocytic leukemia. 
[20] CD95 expression is epigenetically regulated. We and 
others have reported that CD95 expression decreases 
due to hypermethylation and chromatin enrichment of 
repressive marks at the CD95 promoter core as MDS 
disease progresses to AML. [19, 21] These two mechanisms 
of regulation are not mutually exclusive and may support 
the difference of CD95 expression between early MDS 
and secondary AML. However, CD95 expression does not 
affect event-free survival suggesting that variation of CD95 
level would not be a unique determinant for MDS disease 
progression to AML.
Figure 2: Impact of CD95 expression on survival and event-free survival. A. Overall survival according to CD95 RFI in 153 
MDS patients. B. Event-free survival according to CD95 RFI. Data are plotted as a Kaplan-Meier curve. Log Rank test for P values.
Oncotarget14905www.impactjournals.com/oncotarget
We show that expression of membrane-bound 
CD95L on CD45low cells was equivalent in MDS 
compared to controls. Previous works reported that soluble 
CD95L was not increased in MDS peripheral blood. [22, 
23] Furthermore, the percentage of CD95L positive cells 
could be lower in MDS peripheral blood compared to 
healthy controls. [24] In contrast, increased membrane 
CD95L expression on myeloid blasts, erythroblasts and 
Figure 3: APG 101 improves the proliferation of erythroid progenitors of BFU-E type and of erythroid precursors by 
inhibiting apoptosis. Erythroblasts were derived from CD34+ progenitors in liquid culture (controls, n=3; MDS, n=5 including 2 RA, 2 
RCMD, 1 RARS). A. Cells were harvested at day 5 of the culture and seeded at 104 cells/mL in the presence of increasing concentrations 
of APG101 in methylcellulose medium for colony assays. BFU-E were quantified after 10 days. Controls plotted as white bars, MDS as 
gray bars. B. APG101 (10 μg/mL) was added and renewed every two days from day 10 to 17. Amplification rate was evaluated by cell 
counting every two days. Controls as dotted lines, MDS as full lines. C. Erythroid cell differentiation was assessed at day 12 by cytological 
examination of May-Grünwald-Giemsa-stained cytospins (left panel) or by flow cytometry using a double labeling with CD71 and CD235a 
to glycophorin A (GPA) antibodies (right panel). Results are representative of 3 experiments. D. Apoptosis was quantified in CD71+ GPA- 
and CD71+ GPA+ cell populations by flow cytometry in 5 cases of MDS and 3 controls. Results expressed as means ± SEM. Mann-Whitney 
test for P values. *: < 0.05.
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maturing myeloid cells of MDS bone marrow has been 
reported. [25] The reason for this discrepancy with our 
results showing a normal level of CD95L on immature 
CD45low cells could be due to technical issues. Indeed, 
immunohistochemical staining of bone marrow samples 
used in the Gupta’s study could be less quantitative than 
flow cytometry. CD95 is overexpressed on immature 
erythroblasts but also on CD34+ progenitors including 
leukemic blasts. [4] Therefore, trapping CD95 ligand 
using APG101 could protect blast cells from apoptosis. We 
report here that CD95L is not overexpressed on CD45low 
and CD71+ myeloid precursors (not shown) in MDS 
marrow, while it is upregulated on maturing erythroblasts. 
[4] Of note, the granulo-monocytic lineage would more 
predominantly express the TNF-related apoptosis-inducing 
ligand (TRAIL) and its receptors. [5, 35] Furthermore, in 
vitro treatment with APG101 does not provoke a raise of 
CFU-L and CFU-GM colonies. The overall selectivity of 
APG101 for CD95L is higher by at least a factor of 100 
than for other apoptosis inducing ligands of the tumor 
necrosis factor superfamily (LIGHT, TRAIL and TNFα). 
Therefore, our results suggest that leukemic progenitors 
and myeloid precursors other than erythroblasts are not 
target cells for APG101.
Alternative therapeutic strategies are needed to 
treat anemia in ESA-resistant lower risk MDS patients. 
Lenalidomide has been shown to induce ESA response in 
30% of cases with an improvement of the response rate 
up to 50% when erythropoietin (EPO) was combined to 
lenalidomide. [26] But, half of the patients remained non-
responders to this second line of treatment. Interestingly, 
the activin IIB ligand trap, luspatercept, gave promising 
results in a phase 2 study designed to correct ineffective 
erythropoiesis in low/int-1 ESA-resistant patients. [27] In 
the present preclinical study, we propose APG101 in the 
treatment of anemia in patients with severe impairment 
Figure 4: Effects of APG101 on the growth of hematopoietic progenitors. Bone marrow mononuclear cells (3 5q- syndrome, 
3 RA, 1 RARS, 2 RCMD-RS, 5 RCMD, 6 RAEB1, 5 controls). were seeded at 105 cells/mL in methylcellulose medium in the presence of 
increasing concentrations of APG101. BFU-E and CFU-GM were counted at day 14 and CFU-E and CFU-L were counted at day 7. “Low” 
MDS (n=15) were defined as MDS with a significant lower BFU-E number compared to controls, and “normal” MDS (n=5) were defined 
as MDS with a BFU-E number equivalent to controls. Results are expressed as colony numbers. Horizontal bars represent medians and 1st 
and 99th centiles. Kruskal-Wallis test for P values.
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of erythropoiesis. APG101 rescued BFU-E growth in 
MDS samples and increased the number of differentiated 
precursors by reducing apoptosis. Caspases are massively 
activated when MDS erythroblasts enter the final phase of 
maturation, [28] while normal erythroid cell differentiation 
requires a limited activation of caspases. [29, 30] We 
have previously demonstrated that controlling the level of 
caspase activation by expressing a dominant negative Fas-
associated death domain (FADD) or Bcl-2 does not impair 
the differentiation capacities of MDS erythroblasts. [5, 
31] Here, we show that APG101 preserves the capacity of 
MDS erythroblasts to differentiate in vitro while reducing 
their apoptotic level. In other pathological situations, 
activation of CD95 pathway protects cells from death. 
CD95 or CD95L invalidation may induce a necrotic death 
closed to a mitotic catastrophe in ovarian or liver cancer 
cells. [32] Furthermore, CD95 stimulates the metastatic 
dissemination in progressive glioblastoma and a phase 
II clinical trial shows that invasion can be blocked by 
weekly administration of APG101. [33, 34] The interim 
report of a phase I clinical trial of APG101 in 5 low/int-
1 transfusion-dependent MDS patients receiving weekly 
intravenous infusions of 100 mg or 400 mg APG101 for 12 
weeks reported an increase of BFU-E/CFU-E and CFU-GM 
progenitors, no increase of medullary blasts after a 6-month 
follow-up, no side effects, and a decrease of transfusion 
Figure 5: Low progenitor cell number, but not CD95 or CD95L expression at baseline is predictive of the response 
to APG101. A. CD95 and CD95L were quantified by flow cytometry and expressed as RFI. B. Bone marrow mononuclear cells were 
seeded at 105 cells/mL in methylcellulose. BFU-E and CFU-GM were counted after 14 days and CFU-E and CFU-L were counted after 7 
days. Results are expressed as colony numbers. White boxes for responders and gray boxes for non-responders. Horizontal bars represent 
medians and 1st and 99th centiles. Student t-test for P values.
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frequencies in 4 patients. [36] These encouraging data must 
be confirmed on a larger cohort of patients.
In conclusion, we have shown that overexpression 
of CD95 at diagnosis is a hallmark of ESA resistance 
and that severe impairment of hematopoiesis is 
predictive of erythroid response to APG101 in vitro. 
Altogether, these data provide a rationale for further 
clinical investigation.
MATERIALS AND METHODS
Patients
MDS patients (n=250) attending Cochin hospital 
were prospectively enrolled between January 2004 to 
July 2012 in a monocentric observational study, after 
they gave informed consent according to the local ethics 
committee recommendations. Inclusion criteria were a 
diagnosis of MDS according to the WHO classification 
and a sample collection at diagnosis and before disease-
modifying treatments. Patients with idiopathic cytopenia 
of undetermined significance or with AML were excluded. 
WHO classification was 5q- syndrome/refractory anemia 
(RA)/MDS-U n=54; RA with ring sideroblasts (RARS)/
refractory cytopenia with multilineage dysplasia (RCMD) 
and ring sideroblasts n=56; RCMD n=51; RA with excess 
of blasts type 1 (RAEB1) n=66, and RAEB type 2 (RAEB2) 
n=23. IPSS was available for 192 patients and 162 (84.4%) 
patients were classified as lower risk MDS, i.e. low/int-1 
IPSS (Supplementary Table S1). Follow-up information of 
including the date of death or AML transformation, defined 
as a bone marrow blast count ≥ 20%, was obtained at each 
follow-up consultation until the 24th November 2014. 
Patient status was recorded in the national MDS registry 
(http://test.registre-smd.clinfile.com). One hundred and 
thirty-nine MDS patients received ESA and the response 
was evaluated in 118 low/int-1 patients according to the 
International Working Group criteria. [14] CD95 expression 
was studied in the whole cohort while CD95L was studied 
in a subgroup of 82 patients. DNA samples from a subgroup 
of 129 patients were available for the study of CD95 gene 
promoter polymorphisms. Control samples (n=30) were 
from patients matched in age suffering of anemia of other 
origin than MDS, either inflammation or cancer invasion. 
Patients with thalassemia or aplastic anemia were excluded.
Flow cytometry
CD95 expression was quantified by direct labeling 
using the fluorescein isothiocyanate (FITC)-coupled 
CD95 antibody (clone UB-2, Beckman Coulter, Fullerton, 
CA). CD95 ligand (CD95L) was quantified using the 
biotinylated mouse anti-human CD95L (CD178) antibody 
(clone NOK-1, Pharmingen, Becton Dickinson) followed 
by streptavidin-coupled to phycoerythrin (PE). Results 
were expressed as ratio of median fluorescence intensities 
(RFI) between specific and isotype-matched antibodies 
within gated CD45low bone marrow cells. Analyses were 
performed using a Cytomics FC500 apparatus (Beckman 
Coulter) with CXP software.
CD95 gene promoter polymorphisms
Bone marrow mononuclear cells (BMMNC) 
were isolated on Ficoll gradient. DNA was extracted 
using commercial kits (Qiagen, Hilden, Germany). 
Polymorphisms located at -1377nt (rs2234767) and -670nt 
(rs1800682) of the 5’-UTR of the CD95 gene was analyzed 
by PCR and Sanger sequencing on ABI 3300 capillary 
sequencer (Agencourt Bioscience, Beverly, MA, USA) 
using the primers: CD95_RS1377_F: 5'-CCCTCCTT 
CCATTCCTTCTTCCC-3' and CD95_RS1377_R: 5'-C 
CCTTTGCT TAGCCCACTGTTC-3', CD95_RS670_F: 
5'-AGCTGGGGCTATGCGATTTG-3' and CD95_RS 
670_R: 5'-GAGCCTTGGCTAATTGCTGG-3'. Mutation 
Surveyor was used for analysis (SoftGenetic©, Inc., Stat 
College, PA, USA).
Colony assays
Colony assays were performed in 20 low/int-1 MDS 
patients, including 15 patients treated by ESA, 14 of them 
being primary or secondary resistant to this treatment and 
5 controls were isolated on Ficoll gradient and seeded in 
methylcellulose containing IL3, SCF, EPO, GM-CSF and 
G-CSF at 105 cells/mL (Stemcell technologies, Vancouver, 
Canada) with 0 to 10 μg/mL APG101. Colony assays were 
validated by an annual external quality control. Progenitors 
were counted at day 7 for colony-forming unit-erythroid 
(CFU-E) and colony-forming unit-leukemic (CFU-L) and 
at day 14 for burst-forming unit-erythroid (BFU-E) and 
colony-forming unit-granulomonocytic (CFU-GM).
Liquid culture
CD34+ progenitors (MDS = 5; controls = 3) were 
purified from BMMNC using the MidiMac system (Miltenyi 
Biotech, Bergisch Gladbach, Germany), and expanded to the 
erythroid lineage in the presence of erythropoietin (EPO), 
stem cell factor (SCF), insulin-like growth factor-1 (IGF-
1) and dexamethasone until day 10.4 At day 5 of the liquid 
culture, cells were harvested and seeded in methylcellulose 
with 0 to 10 μg/mL APG101. BFU-E and CFU-GM were 
counted after 10 days. From day 10 of the liquid culture, 
erythroid cell maturation was obtained by replacing SCF, 
IGF-1 and dexamethasone by insulin. APG101 (10 μg/mL) 
was added and renewed every two days. Cells were counted 
and erythroid cell differentiation was assessed on May-
Grünwald-Giemsa-stained cytospins and flow cytometry 
using CD71-FITC and glycophorin A (GPA)-PE antibodies. 
Apoptosis was quantified using annexin V-allophycocyanin 
(APC) (Becton-Dickinson).
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Statistical analysis
For continuous variables, values were expressed 
as median and interquartile range (IQR) or 1-99 centiles 
and were compared using Student t, Mann-Whitney, 
ANOVA or Kruskal-Wallis tests. Categorical variables are 
reported as counts and percentages and compared using 
Chi-squared or Fisher’s exact tests. Multivariate analysis 
regarding the response to ESA was performed using 
logistic regression and results were expressed as odds ratio 
and 95% confidence intervals (95% CI). Survival time was 
computed from the time of MDS diagnosis to the time of 
the death for overall survival (OS) or to the time of AML 
transformation for event free survival (EFS). Censoring 
occurred in individuals who were alive (and without 
AML transformation for EFS) at the 24th November 
2014, or who were lost from follow-up before that time. 
Survival was evaluated by the Kaplan-Meier method and 
comparisons were carried out with the Log-Rank test. 
Statistical tests were bilateral and a P-value<0.05 was 
considered to indicate statistical significance. Analyses 
were performed using the GraphPad Prism v.6 (GraphPad 
Software, La Jolla, CA) and Stata version 12 (StataCorp 
L.P., College Station, TX).
ACKNOWLEDGMENTS
Apogenix for research funding. The team is 
supported by the Laboratory of Excellence LabEx GR-
Ex and the Site de Recherche Intégrée sur le Cancer 
CARPEM for CAncer Research for PErsonalized 
Medicine. AR was supported by a PhD fellowship from 
the Fondation ARC pour la Recherche contre le Cancer.
CONFLICTS OF INTEREST
Anna Raimbault, Celine Deudon, Cecile Pierre-
Eugene, Lise Willems, Nicolas Chapuis, Stephanie Mathis, 
Alexandra Rouquette, Olivier Kosmider, Valerie Bardet 
have nothing to disclose. Claudia Kunz, and Harald Fricke 
are APOGENIX employees. Michaela Fontenay received 
research funding from APOGENIX.
Author contributions
A Raimbault, CD, CP-E performed experiments, 
MF, HF, CK designed the study, LW included patients, 
SM, NC, OK, VB, MF analyzed the data, A Rouquette 
performed statistical analyses, MF wrote the manuscript, 
HF and CK critically reviewed the manuscript.
REFERENCES
1. Krammer PH, Behrmann I, Daniel P, Dhein J, Debatin KM. 
Regulation of apoptosis in the immune system. Curr Opin 
Immunol. 1994; 6:279–289. Review.
2. De Maria R, Zeuner A, Eramo A, Domenichelli C, Bonci D, 
Grignani F, Srinivasula SM, Alnemri ES, Testa U, Peschle 
C. Negative regulation of erythropoiesis by caspase-medi-
ated cleavage of GATA-1. Nature. 1999; 401:489–493.
3. Koulnis M, Liu Y, Hallstrom K, Socolovsky M. Negative 
autoregulation by Fas stabilizes adult erythropoiesis and 
accelerates its stress response. PLoS One. 2011; 6: e21192.
4. Claessens YE, Bouscary D, Dupont JM, Picard F, Melle 
J, Gisselbrecht S, Lacombe C, Dreyfus F, Mayeux P, 
Fontenay-Roupie M. In vitro proliferation and differentia-
tion of erythroid progenitors from patients with myelodys-
plastic syndromes: evidence for Fas-dependent apoptosis. 
Blood. 2002 Mar 1;99:1594–601.
5. Claessens YE, Park S, Dubart-Kupperschmitt A, Mariot V, 
Garrido C, Chrétien S, Dreyfus F, Lacombe C, Mayeux P, 
Fontenay M. Rescue of early-stage myelodysplastic syn-
drome-deriving erythroid precursors by the ectopic expres-
sion of a dominant-negative form of FADD. Blood. 2005 
May 15;105:4035–42.
6. Hellström-Lindberg E, Negrin R, Stein R, Krantz S, Lindberg 
G, Vardiman J, Ost A, Greenberg P. Erythroid response to 
treatment with G-CSF plus erythropoietin for the anaemia 
of patients with myelodysplastic syndromes: proposal for a 
predictive model. Br J Haematol. 1997 Nov;99:344–51.
7. Casadevall N, Durieux P, Dubois S, Hemery F, Lepage E, 
Quarré MC, Damaj G, Giraudier S, Guerci A, Laurent G, 
Dombret H, Chomienne C, Ribrag V,. et al. Health, eco-
nomic, and quality-of-life effects of erythropoietin and 
granulocyte colony-stimulating factor for the treatment of 
myelodysplastic syndromes: a randomized, controlled trial. 
Blood. 2004 Jul 15;104:321–7.
8. Hellström-Lindberg E, Gulbrandsen N, Lindberg G, 
Ahlgren T, Dahl IM, Dybedal I, Grimfors G, Hesse-Sundin 
E, Hjorth M, Kanter-Lewensohn L, Linder O, Luthman M, 
Löfvenberg E, et al; Scandinavian MDS Group. A validated 
decision model for treating the anaemia of myelodysplas-
tic syndromes with erythropoietin + granulocyte colony-
stimulating factor: significant effects on quality of life. Br J 
Haematol. 2003 Mar;120:1037–46.
9. Park S, Grabar S, Kelaidi C, Beyne-Rauzy O, Picard F, 
Bardet V, Coiteux V, Leroux G, Lepelley P, Daniel MT, 
Cheze S, Mahé B, Ferrant A et al; GFM group (Groupe 
Francophone des Myélodysplasies). Predictive factors of 
response and survival in myelodysplastic syndrome treated 
with erythropoietin and G-CSF: the GFM experience. 
Blood. 2008 Jan 15;111:574–82.
10. Westers TM, Alhan C, Chamuleau ME, van der Vorst 
MJ, Eeltink C, Ossenkoppele GJ, van de Loosdrecht AA. 
Aberrant immunophenotype of blasts in myelodysplastic 
syndromes is a clinically relevant biomarker in predict-
ing response to growth factor treatment. Blood. 2010 Mar 
4;115:1779–84.
11. Jädersten M, Malcovati L, Dybedal I, Della Porta MG, 
Invernizzi R, Montgomery SM, Pascutto C, Porwit A, 
Cazzola M, Hellström-Lindberg E. Erythropoietin and 
Oncotarget14910www.impactjournals.com/oncotarget
granulocyte-colony stimulating factor treatment associated 
with improved survival in myelodysplastic syndrome. J Clin 
Oncol. 2008 Jul 20;26:3607–13.
12. Greenberg PL, Sun Z, Miller KB, Bennett JM, Tallman MS, 
Dewald G, Paietta E, van der Jagt R, Houston J, Thomas 
ML, Cella D, Rowe JM. Treatment of myelodysplastic syn-
drome patients with erythropoietin with or without granulo-
cyte colony-stimulating factor: results of a prospective ran-
domized phase 3 trial by the Eastern Cooperative Oncology 
Group (E1996). Blood. 2009 Sep 17;114:2393–400.
13. Frisan E, Pawlikowska P, Pierre-Eugène C, Viallon 
V, Gibault L, Park S, Mayeux P, Dreyfus F, Porteu 
F, Fontenay M. p-ERK1/2 is a predictive factor of 
response to erythropoiesis-stimulating agents in low/
int-1 myelodysplastic syndromes. Haematologica. 2010 
Nov;95:1964–8.
14. Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, 
Wijermans PW, Nimer SD, Pinto A, Beran M, de Witte 
TM, Stone RM, Mittelman M, Sanz GF, Gore SD et al. 
Clinical application and proposal for modification of the 
International Working Group (IWG) response criteria in 
myelodysplasia. Blood. 2006 Jul 15;108:419–25. E
15. Crew KD, Gammon MD, Terry MB, Zhang FF, Agrawal 
M, Eng SM, Sagiv SK, Teitelbaum SL, Neugut AI, 
Santella RM. Genetic polymorphisms in the apoptosis-
associated genes FAS and FASL and breast cancer risk. 
Carcinogenesis. 2007 Dec;28:2548–51.
16. Sibley K, Rollinson S, Allan JM, Smith AG, Law 
GR, Roddam PL, Skibola CF, Smith MT, Morgan GJ. 
Functional FAS promoter polymorphisms are associated 
with increased risk of acute myeloid leukemia. Cancer Res. 
2003 Aug 1;63:4327–30.
17. Lee YH, Bae SC, Choi SJ, Ji JD, Song GG. Associations 
between the FAS -670 A/G and -1,377 G/A poly-
morphisms and susceptibility to autoimmune rheu-
matic diseases: a meta-analysis. Mol Biol Rep. 2012 
Dec;39:10671–9.
18. Huang Q, Wang J, Hu Y. FAS-670 gene polymorphism and 
cervical carcinogenesis risk: A meta-analysis. Biomed Rep. 
2013 Nov;1:889–894.
19. Ettou S, Audureau E, Humbrecht C, Benet B, Jammes H, 
Clozel T, Bardet V, Lacombe C, Dreyfus F, Mayeux P, 
Solary E, Fontenay M. Fas expression at diagnosis as a bio-
marker of azacitidine activity in high-risk MDS and second-
ary AML. Leukemia. 2012 Oct;26:2297–9.
20. Sunter NJ, Scott K, Hills R, Grimwade D, Taylor S, 
Worrillow LJ, Fordham SE, Forster VJ, Jackson G, Bomken 
S, Jones G, Allan JM. A functional variant in the core pro-
moter of the CD95 cell death receptor gene predicts prog-
nosis in acute promyelocytic leukemia. Blood. 2012 Jan 
5;119:196–205.
21. Karlic H, Herrmann H, Varga F, Thaler R, Reitermaier 
R, Spitzer S, Ghanim V, Blatt K, Sperr WR, Valent P, 
Pfeilstöcker M. The role of epigenetics in the regulation of 
apoptosis in myelodysplastic syndromes and acute myeloid 
leukemia. Crit Rev Oncol Hematol. 2014 Apr;90:1–16.
22. Munker R, Midis G, Owen-Schaub L, Andreff M. Soluble 
FAS (CD95) is not elevated in the serum of patients with 
myeloid leukemias, myeloproliferative and myelodysplastic 
syndromes. Leukemia. 1996 Sep;10:1531–3.
23. Salih HR, Nuessler V, Denzlinger C, Starling GC, Kiener 
PA, Schmetzer HM. Serum levels of CD137 ligand and 
CD178 are prognostic factors for progression of myelodys-
plastic syndrome. Leuk Lymphoma. 2004 Feb;45:301–8.
24. Hirano T, Hiratsuka N, Iwahori T, Oka K, Wakasugi K. 
Fas/Fas-ligand expressions in peripheral-blood mononu-
clear cells of patients with myelodysplastic syndromes. Res 
Commun Mol Pathol Pharmacol. 2003;113-114:315–28.
25. Gupta P, Niehans GA, LeRoy SC, Gupta K, Morrison VA, 
Schultz C, Knapp DJ, Kratzke RA. Fas ligand expression 
in the bone marrow in myelodysplastic syndromes corre-
lates with FAB subtype and anemia, and predicts survival. 
Leukemia. 1999 Jan;13:44–53.
26. Toma A, Kosmider O, Chevret S, Delaunay J, Stamatoullas 
A, Rose C, Beyne-Rauzy O, Banos A, Guerci-Bresler A, 
Wickenhauser S, Caillot D, Laribi K, De Renzis B, et al. 
Lenalidomide with or without erythropoietin in transfusion 
dependent erythropoiesis-stimulating agent-refractory lower 
risk MDS without 5q deletion. Leukemia. 2015 Oct 26. doi: 
10.1038/leu.2015.296. [Epub ahead of print]
27. Giagounidis A, Platzbecker U, Germing U, Götze K, Kiewe 
P, Mayer KT, Ottmann O, Radsak M, Wolff T, Haas D, 
Hankin M, Wilson D, Zhang X, Laadem A, Sherman ML, 
Attie KM. Luspatercept Treatment Leads to Long Term 
Increases in Hemoglobin and Reductions in Transfusion 
Burden in Patients with Low or Intermediate-1 Risk 
Myelodysplastic Syndromes (MDS): Preliminary Results 
from the Phase 2 PACE-MDS. Blood. 2015. 126 (25) Abs 
92.
28. Frisan E, Vandekerckhove J, de Thonel A, Pierre-Eugène 
C, Sternberg A, Arlet JB, Floquet C, Gyan E, Kosmider O, 
Dreyfus F, Gabet AS, Courtois G, Vyas P et al. Defective 
nuclear localization of Hsp70 is associated with dyseryth-
ropoiesis and GATA-1 cleavage in myelodysplastic syn-
dromes. Blood. 2012 Feb 9;119:1532–42.
29. Zermati Y, Garrido C, Amsellem S, Fishelson S, Bouscary 
D, Valensi F, Varet B, Solary E, Hermine O. Caspase acti-
vation is required for terminal erythroid differentiation. J 
Exp Med. 2001 Jan 15;193:247–54.
30. Carlile GW, Smith DH, Wiedmann M. Caspase-3 has a 
nonapoptotic function in erythroid maturation. Blood. 2004 
Jun 1;103:4310–6.
31. Gyan E, Frisan E, Beyne-Rauzy O, Deschemin JC, Pierre-
Eugene C, Randriamampita C, Dubart-Kupperschmitt A, 
Garrido C, Dreyfus F, Mayeux P, Lacombe C, Solary E, 
Fontenay M. Spontaneous and Fas-induced apoptosis of 
low-grade MDS erythroid precursors involves the endoplas-
mic reticulum. Leukemia. 2008 Oct;22:1864–73.
Oncotarget14911www.impactjournals.com/oncotarget
32. Hadji A, Ceppi P, Murmann AE, Brockway S, Pattanayak A, 
Bhinder B, Hau A, De Chant S, Parimi V, Kolesza P, Richards 
J, Chandel N, Djaballah H et al. Death induced by CD95 or 
CD95 ligand elimination. Cell Rep. 2014 Apr 10;7:208–22.
33. Kleber S, Sancho-Martinez I, Wiestler B, Beisel A, Gieffers 
C, Hill O, Thiemann M, Mueller W, Sykora J, Kuhn A, 
Schreglmann N, Letellier E, Zuliani C et al. Yes and PI3K 
bind CD95 to signal invasion of glioblastoma. Cancer Cell. 
2008 Mar;13:235–48
34. Wick W, Fricke H, Junge K, Kobyakov G, Martens T, 
Heese O, Wiestler B, Schliesser MG, von Deimling A, 
Pichler J, Vetlova E, Harting I, Debus J et al. A phase II, 
randomised, study of weekly APG101 + reirradiation versus 
reirradiation in progressive glioblastoma. Clin Cancer Res. 
2014 Dec 15;20:6304–13
35. Zang DY, Goodwin RG, Loken MR, Bryant E, Deeg HJ. 
Expression of tumor necrosis factor-related apoptosis-
inducing ligand, Apo2L, and its receptors in myelodys-
plastic syndrome: effects on in vitro hematopoiesis. Blood. 
2001 Nov 15;98:3058–65.
36. launiger-Lörsch E, Luft T, Fey S, Obländer J, Brendel S, 
Pressler J, Jan J-Cn, Kunz C, Ho AD, Fricke H, Mossner 
M, Metzgeroth G, Nowak D et al. The Fas Ligand Inhibitor 
APG101 in Transfusion Dependent Patients with Low Risk 
MDS: Interim Results from a Phase I Study. Blood. 2014 
124:4669.
